← Back to Screener
Cumberland Pharmaceuticals Inc (CPIX)
Price$5.80
Value ScoreD
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)148.71%
Price vs S&P 500 (4W)23.94%
VGM Score51.07
Market Capitalization$86.90M
All Metrics
P/CF (Annual)17.62x
Book Value / Share (Quarterly)$1.44
P/TBV (Annual)5.49x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)1.95%
Cash Flow / Share (Quarterly)$0.09
Price vs S&P 500 (YTD)37.57%
Gross Margin (TTM)82.89%
Net Profit Margin (TTM)-17.26%
EPS (TTM)$-0.49
10-Day Avg Trading Volume0.14M
EPS Excl Extra (TTM)$-0.49
Revenue Growth (5Y)3.53%
EPS (Annual)$-0.19
ROI (Annual)-9.42%
Gross Margin (Annual)85.02%
Net Profit Margin (5Y Avg)-12.47%
Cash / Share (Quarterly)$0.73
Revenue Growth QoQ (YoY)-22.04%
ROA (Last FY)-3.69%
Revenue Growth TTM (YoY)2.08%
EBITD / Share (TTM)$-0.20
ROE (5Y Avg)-16.90%
Operating Margin (TTM)-17.20%
Cash Flow / Share (Annual)$0.32
P/B Ratio4.02x
P/B Ratio (Quarterly)2.25x
Net Income / Employee (Annual)$-30,500
EV / Revenue (TTM)1.93x
Net Interest Coverage (TTM)-145.11x
ROA (TTM)-10.28%
EV / EBITDA (TTM)65.29x
EPS Incl Extra (Annual)$-0.19
Current Ratio (Annual)1.01x
Quick Ratio (Quarterly)0.73x
3-Month Avg Trading Volume0.74M
52-Week Price Return7.41%
EV / Free Cash Flow (Annual)17.08x
Revenue / Employee (TTM)$451,000
Tangible BV / Share (Quarterly)$0.59
P/S Ratio (Annual)1.95x
Asset Turnover (Annual)0.58x
52-Week High$6.61
Operating Margin (5Y Avg)-16.47%
EPS Excl Extra (Annual)$-0.19
CapEx CAGR (5Y)-38.72%
Tangible BV CAGR (5Y)-10.50%
26-Week Price Return156.64%
Quick Ratio (Annual)0.77x
13-Week Price Return64.77%
Total Debt / Equity (Annual)0.21x
Current Ratio (Quarterly)0.95x
Enterprise Value$81.14M
Revenue / Share Growth (5Y)3.95%
Asset Turnover (TTM)0.60x
Book Value / Share Growth (5Y)-11.89%
Revenue / Employee (Annual)$478,700
Inventory Turnover (Annual)1.30x
Pretax Margin (Annual)-6.31%
Cash / Share (Annual)$0.77
3-Month Return Std Dev82.26%
Gross Margin (5Y Avg)82.24%
Net Income / Employee (TTM)$-77,800
ROE (Last FY)-11.40%
Net Interest Coverage (Annual)-156.38x
EPS Basic Excl Extra (Annual)$-0.19
P/FCF (TTM)65.53x
Receivables Turnover (TTM)3.39x
EV / Free Cash Flow (TTM)63.12x
Total Debt / Equity (Quarterly)0.24x
EPS Incl Extra (TTM)$-0.49
Receivables Turnover (Annual)3.11x
ROI (TTM)-23.81%
P/S Ratio (TTM)2.07x
Pretax Margin (5Y Avg)-13.61%
Revenue / Share (Annual)$3.00
Tangible BV / Share (Annual)$0.73
Free OCF CAGR (5Y)7.49%
Price vs S&P 500 (52W)-16.96%
Year-to-Date Return45.73%
5-Day Price Return1.75%
EPS Normalized (Annual)$-0.19
ROA (5Y Avg)-6.02%
Net Profit Margin (Annual)-6.37%
Month-to-Date Return-5.69%
Cash Flow / Share (TTM)$0.12
EBITD / Share (Annual)$0.09
Operating Margin (Annual)-6.27%
LT Debt / Equity (Annual)0.21x
P/CF (TTM)61.15x
ROI (5Y Avg)-11.58%
LT Debt / Equity (Quarterly)0.24x
EPS Basic Excl Extra (TTM)$-0.49
P/TBV (Quarterly)5.50x
P/B Ratio (Annual)2.39x
Inventory Turnover (TTM)1.50x
Pretax Margin (TTM)-17.17%
Book Value / Share (Annual)$1.66
Price vs S&P 500 (13W)56.52%
Beta0.12x
P/FCF (Annual)18.29x
Revenue / Share (TTM)$2.80
ROE (TTM)-28.77%
52-Week Low$1.85
vGradeD
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.13est. —
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CPIXCumberland Pharmaceuticals Inc | D | C | B | $5.80 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops, and commercializes branded prescription drugs targeting hospital acute care, gastroenterology, rheumatology, and oncology. The company generates revenue from its portfolio of FDA-approved brands including Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol, and Vibativ, which it distributes through dedicated US sales divisions and international partner networks.